Medicare GLP-1 Bridge Program Eligibility: Do You Qualify for the $50 Copay in 2026?
Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.
The bottom line, before you scroll
You likely qualify if you’re 18 or older, enrolled in an eligible Medicare Part D plan for 2026, and your prescriber writes Foundayo, Wegovy (injection or tablets), or Zepbound KwikPen for weight management — and you meet at least one of CMS’s three clinical paths: BMI ≥ 35 alone, BMI ≥ 30 with HFpEF, uncontrolled hypertension, or CKD stage 3a+, or BMI ≥ 27 with prediabetes, prior heart attack, prior stroke, or symptomatic PAD.
Six questions. One verdict. Clear next step. No signup required.
The Medicare GLP-1 Bridge in 90 Seconds — What Changed in April 2026
April 6, 2026 — Drug list updated
CMS updated the Bridge drug list. Foundayo (orforglipron, Eli Lilly’s oral GLP-1) was added after FDA approval, and Zepbound was narrowed to the KwikPen formulation only. Single-dose vials and single-dose pens of Zepbound are not covered through the Bridge. If your prescriber writes “Zepbound 2.5 mg/0.5 mL single-dose pen,” that prescription doesn’t qualify even if you do.
April 21, 2026 — Extended through December 31, 2027
CMS extended the Bridge from 6 months to 18 months. Reason: not enough Part D plan sponsors signed up for the BALANCE Model, so CMS couldn’t hit the 80% participation threshold needed to launch BALANCE in Medicare in 2027. The Bridge fills the gap. Good news: you have a longer window, and Part D sponsors do not need to opt into the Bridge for eligible beneficiaries.
Here’s the context most articles skip: federal law has prohibited Medicare from covering medications prescribed solely for weight loss since 2003. For 23 years, Medicare beneficiaries who wanted Wegovy or Zepbound for weight management had to pay cash — usually $1,000+/month at list price. The Bridge is a CMS short-term demonstration that operates outside the normal Part D coverage and payment flow under Section 402 demonstration authority.
Quick Verdict Table
For people who skip the tool. Find your row.
| Your situation | Likely answer |
|---|---|
| BMI ≥ 35, in eligible Part D plan, weight-loss prescription for Foundayo, Wegovy, or Zepbound KwikPen | ✅ Tier 1 — likely qualify |
| BMI 30–34.9 + HFpEF, uncontrolled hypertension on 2+ meds, or CKD stage 3a+ | ✅ Tier 2 — likely qualify |
| BMI 27–29.9 + prediabetes, prior heart attack, prior stroke, or symptomatic PAD | ✅ Tier 3 — likely qualify |
| BMI under 27, OR no qualifying condition with BMI between 27–34.9 | ❌ Bridge doesn't apply |
| Original Medicare only (no Part D) | ❌ Must enroll in Part D first |
| In PFFS, Section 1876, PACE, or similar plan type | ❌ Generally ineligible |
| Already getting GLP-1 through Part D for diabetes / CV / sleep apnea | ⚠️ Use Part D — often better deal |
| Prescribed Zepbound vials or single-dose pens | ❌ Bridge covers KwikPen only |
| Prescribed Ozempic, Mounjaro, or Rybelsus for weight loss | ❌ Not on Bridge drug list |
Six questions. One verdict. Clear next step. No signup required.
Medicare GLP-1 Bridge Program Eligibility: The 4 Gates You Have to Clear
Enrollment in an eligible Medicare Part D plan for 2026
You must be enrolled in a qualifying Part D plan type during calendar year 2026. The Bridge requires Part D enrollment because it's structured as a Part D demonstration even though it operates outside the normal Part D payment flow. Original Medicare alone doesn't count. We'll break down which plan types qualify below.
Age 18 or older
You must be 18 or older at the time of the prior authorization request. This is rarely an issue for Medicare beneficiaries, but CMS lists it explicitly because the Bridge is technically open to disabled adults under 65 enrolled in Medicare Part D.
Weight-loss indication with lifestyle modification
The prescription must be specifically for 'reducing excess body weight and maintaining weight reduction in combination with current and ongoing lifestyle modification including structured nutrition and physical activity consistent with the applicable FDA approved label.' If your prescription is for type 2 diabetes, cardiovascular risk reduction, or obstructive sleep apnea, that's a different pathway — those go through standard Part D, not the Bridge.
Meet at least one of three BMI/condition tiers
You only need to meet one tier. Bring documentation for every relevant condition so your prescriber can choose the most accurate qualifying route on the prior authorization. We'll break down each tier in the next section.
The Three BMI/Condition Tiers, Explained Plainly
CMS eligibility logic:
You qualify if:
(Age ≥ 18) AND (eligible Part D plan) AND (weight-loss Rx)
AND ONE of the following:
• Tier 1: BMI ≥ 35 at therapy initiation
• Tier 2: BMI ≥ 30 AND ONE of:
- HFpEF (heart failure with preserved ejection fraction)
- Uncontrolled hypertension (SBP > 140 or DBP > 90
on 2+ antihypertensives)
- CKD Stage 3a or above (eGFR ≤ 59 mL/min)
• Tier 3: BMI ≥ 27 AND ONE of:
- Prediabetes (per ADA guidelines)
- Prior myocardial infarction
- Prior stroke
- Symptomatic peripheral artery diseaseIf your BMI is 35 or higher at the time you start (or started) GLP-1 therapy, no additional medical condition is required. Your provider attests to your BMI and your commitment to lifestyle modification.
| Height | Weight at BMI 35 |
|---|---|
| 5′2″ | ~191 lbs |
| 5′4″ | ~204 lbs |
| 5′6″ | ~217 lbs |
| 5′8″ | ~230 lbs |
| 5′10″ | ~244 lbs |
| 6′0″ | ~258 lbs |
| 6′2″ | ~273 lbs |
Heart failure with preserved ejection fraction (HFpEF) — diagnosed through an echocardiogram showing an ejection fraction ≥ 50% along with symptoms of heart failure. Routine “heart failure” without the HFpEF distinction may not be enough — confirm with your cardiologist.
Uncontrolled hypertension — strict definition: SBP > 140 mm Hg or DBP > 90 mm Hg, while already taking two or more antihypertensive medications. Regular hypertension that’s controlled with medication does not qualify.
Chronic kidney disease (CKD) stage 3a or above — eGFR ≤ 59 mL/min. Stage 3a is eGFR 45–59. Stage 3b is 30–44. Your basic metabolic panel shows your eGFR — ask your doctor’s office to confirm the current stage.
Prediabetes — defined per ADA guidelines: A1C between 5.7 and 6.4%, fasting plasma glucose between 100 and 125 mg/dL, or 2-hour OGTT glucose between 140 and 199 mg/dL. Any one is enough. Many Medicare beneficiaries have prediabetes documented in their charts and don’t realize it qualifies them.
Prior myocardial infarction — any documented heart attack at any point. Discharge summary or cardiology notes confirm it.
Prior stroke — includes ischemic or hemorrhagic, imaging-confirmed. TIAs are gray area — confirm with your neurologist whether your specific event qualifies.
Symptomatic peripheral artery disease — PAD with claudication, rest pain, or ulceration documented by your vascular specialist, often supported by ankle-brachial index (ABI) testing.
Combined BMI reference table
| Height | BMI 27 (Tier 3 floor) | BMI 30 (Tier 2 floor) | BMI 35 (Tier 1 standalone) |
|---|---|---|---|
| 5′0″ | ~138 lbs | ~153 lbs | ~179 lbs |
| 5′2″ | ~148 lbs | ~164 lbs | ~191 lbs |
| 5′4″ | ~157 lbs | ~174 lbs | ~204 lbs |
| 5′6″ | ~167 lbs | ~186 lbs | ~217 lbs |
| 5′8″ | ~177 lbs | ~197 lbs | ~230 lbs |
| 5′10″ | ~188 lbs | ~209 lbs | ~244 lbs |
| 6′0″ | ~199 lbs | ~221 lbs | ~258 lbs |
| 6′2″ | ~211 lbs | ~234 lbs | ~273 lbs |
Six questions. One verdict. Clear next step. No signup required.
Is Your Medicare Plan Eligible? CMS-Listed Plan Types
| Plan Type | Eligible? | Notes |
|---|---|---|
| Standalone PDP (Prescription Drug Plan) | ✓ Yes | Directly eligible |
| Medicare Advantage HMO with drug coverage (MA-PD HMO) | ✓ Yes | Coordinated care plan |
| Medicare Advantage HMOPOS with drug coverage | ✓ Yes | Coordinated care plan |
| Medicare Advantage Local PPO with drug coverage | ✓ Yes | Coordinated care plan |
| Medicare Advantage Regional PPO with drug coverage | ✓ Yes | Coordinated care plan |
| Special Needs Plan (D-SNP, C-SNP, I-SNP) | ✓ Yes | Specifically listed in CMS FAQ |
| Employer/Union Group Waiver Plan (EGWP) | ✓ Yes | Specifically listed in CMS FAQ |
| Limited Income Newly Eligible Transition (LI NET) | ✓ Yes | Specifically listed in CMS FAQ |
| Private Fee-for-Service (PFFS) plan | ✕ No | Unless also enrolled in standalone PDP |
| Section 1876 cost contract plan | ✕ No | Unless also enrolled in standalone PDP |
| Section 1833 health care prepayment plan | ✕ No | Unless also enrolled in standalone PDP |
| PACE (Programs of All-Inclusive Care for the Elderly) | ✕ No | Unless also enrolled in standalone PDP |
| Fallback plan | ✕ No | Unless also enrolled in standalone PDP |
| Religious Fraternal Benefit (RFB) plan | ✕ No | Unless also enrolled in standalone PDP |
| Original Medicare only (no Part D) | ✕ No | Must enroll in a Part D plan first |
| Medicaid only (no Medicare) | ✕ No | Bridge is Medicare-only |
Dual eligibility doesn’t disqualify you. If you’re enrolled in both Medicare and Medicaid, you can still use the Bridge as long as your Part D plan type is on the eligible list. CMS specifically confirms this.
If you don’t know your plan type: Look at your insurance card, or call 1-800-MEDICARE (1-800-633-4227) for free help. Or log into Medicare.gov and view your plan details.
Which Medications the Bridge Actually Covers (And the KwikPen Catch)
Covered under the Bridge
| Medication | Active ingredient | Form | Bridge-covered? |
|---|---|---|---|
| Foundayo (orforglipron) | orforglipron | All formulations (oral) | ✓ Yes |
| Wegovy injection | semaglutide | Subcutaneous injection | ✓ Yes |
| Wegovy tablets (Wegovy pill) | semaglutide | Oral tablet | ✓ Yes |
| Zepbound KwikPen | tirzepatide | Multi-dose pen | ✓ Yes |
| Zepbound single-dose vial | tirzepatide | Vial | ✕ Not covered |
| Zepbound single-dose pen | tirzepatide | Single-use pen | ✕ Not covered |
Not covered under the Bridge
| Medication | Why not |
|---|---|
| Ozempic (semaglutide) | FDA-approved for type 2 diabetes — covered through standard Part D if you have diabetes |
| Mounjaro (tirzepatide) | FDA-approved for type 2 diabetes — covered through standard Part D if you have diabetes |
| Rybelsus (oral semaglutide) | FDA-approved for type 2 diabetes — covered through standard Part D if you have diabetes |
| Saxenda (liraglutide) | Not on the Bridge drug list |
| Compounded semaglutide or tirzepatide | Not FDA-approved finished products; not part of the Medicare GLP-1 Bridge |
The Zepbound formulation trap — the one most likely to trip you up
The Bridge covers Zepbound KwikPen only. If your prescriber writes “Zepbound 2.5 mg/0.5 mL single-dose pen” or “Zepbound vial,” the prescription doesn’t qualify even if you do. The KwikPen is a multi-dose injection device. The single-dose pen and vial are different products — same drug (tirzepatide), different delivery.
When you talk to your prescriber, say specifically: “Will this be the Zepbound KwikPen formulation? That’s the one the Medicare Bridge covers.”
Qualifying Medical Conditions, in Plain English
| Condition | Tier | CMS criterion | Usual documentation | Ask your prescriber |
|---|---|---|---|---|
| HFpEF | Tier 2 (BMI ≥ 30) | Diagnosed HFpEF | Echo showing EF ≥ 50% + cardiology notes | "Is my heart failure documented as HFpEF specifically?" |
| Uncontrolled hypertension | Tier 2 (BMI ≥ 30) | SBP > 140 or DBP > 90 while on 2+ antihypertensives | Recent BP readings + medication list | "Am I documented as uncontrolled despite 2+ BP meds?" |
| CKD stage 3a or above | Tier 2 (BMI ≥ 30) | eGFR ≤ 59 mL/min | Basic metabolic panel with eGFR | "What's my current CKD stage?" |
| Prediabetes (ADA) | Tier 3 (BMI ≥ 27) | A1C 5.7–6.4%, FPG 100–125, or OGTT 140–199 mg/dL | Lab results | "Do my labs document prediabetes per ADA criteria?" |
| Prior myocardial infarction | Tier 3 (BMI ≥ 27) | Documented heart attack (any time) | Discharge summary or cardiology notes | "Is my prior heart attack in my chart?" |
| Prior stroke | Tier 3 (BMI ≥ 27) | Ischemic or hemorrhagic, imaging-confirmed | Neurology notes or imaging report | "Does my chart document the prior stroke clearly?" |
| Symptomatic PAD | Tier 3 (BMI ≥ 27) | PAD with claudication, rest pain, or ulceration | Vascular specialist notes; ABI testing | "Is my PAD documented as symptomatic?" |
What Your Doctor Needs to Submit (and What to Bring)
The 6 things to bring to your provider visit
- 1Your current BMI — or your height and weight so the office can calculate it. If you're borderline, get measured at the office; home scales drift.
- 2Records of your qualifying condition — labs (A1C, eGFR), imaging (echo, MRI), specialist notes (cardiology, nephrology, neurology, vascular).
- 3Your current medication list — particularly important if you're using uncontrolled hypertension as your qualifier, because the criterion requires 2+ BP meds.
- 4Documentation of structured nutrition and physical activity — your provider attests to ongoing lifestyle modification. Bring any program enrollment records you have.
- 5Your Medicare Part D card or plan documents — confirms your plan type is on the eligible list.
- 6Historical weight records (optional but powerful) — if your current BMI is below the tier threshold but you started therapy at a higher BMI, those records let your provider attest to the criterion at therapy initiation.
What to actually say to your doctor
“I’d like to know if I qualify for the Medicare GLP-1 Bridge Program. Can we check whether I meet one of CMS’s three eligibility tiers — BMI ≥ 35 alone, BMI ≥ 30 with HFpEF / uncontrolled hypertension / CKD stage 3a+, or BMI ≥ 27 with prediabetes / prior MI / prior stroke / symptomatic PAD — and whether your office can submit the Bridge prior authorization to the central processor when the program opens July 1, 2026? If Zepbound is the right medication, please specifically prescribe the KwikPen formulation, since that’s what the Bridge covers.”
Where the prior authorization goes (not to your plan)
The prior authorization goes to CMS’s central processor — administered by Humana, the same company that runs the LI NET program — not to your Part D plan. If your Part D plan receives a Bridge PA by mistake, CMS has instructed plans to redirect prescribers to the central processor.
BIN: 028918 | PCN: MEDDGLP1BR
Note: These are pharmacy claim-routing details, not the address where your provider sends the PA.
The $50 Copay — What It Does and Doesn’t Do
What the $50 covers
- ✓A one-month supply of Foundayo, Wegovy (injection or tablets), or Zepbound KwikPen
- ✓Same flat amount regardless of dose
- ✓Same flat amount regardless of which Part D coverage phase you’re in
What the $50 does NOT do
- ✕Does not count toward your Part D deductible
- ✕Does not count toward your $2,100 annual Part D OOP cap (TrOOP)
- ✕Extra Help / LIS does not apply — you pay the full $50 even if you pay $0 for other Part D meds
- ✕Manufacturer copay coupons cannot be applied
- ✕Paper claims / direct member reimbursements not accepted
The honest math
| Time period | Months | Total copay paid |
|---|---|---|
| Original 6-month Bridge (now extended) | 6 | $300 |
| Full extended Bridge (July 2026 – Dec 2027) | 18 | $900 |
| Illustrative: 18 months at list price ($1,000+/mo) | 18 | $18,000+ |
Illustrative comparison. Your actual savings depend on what you’d otherwise pay. Does not account for TrOOP impact or Extra Help.
Bridge vs. Standard Part D — Same Drug, Different Door
| Your situation | Correct pathway | Patient cost rule |
|---|---|---|
| Wegovy or Zepbound KwikPen for weight loss (and you meet a tier) | Medicare GLP-1 Bridge | $50 flat copay; doesn't count toward Part D TrOOP |
| Wegovy for cardiovascular risk reduction (with established CV disease + overweight/obesity) | Standard Part D | Plan's copay; counts toward TrOOP; Extra Help applies if eligible |
| Zepbound for moderate-to-severe obstructive sleep apnea (with obesity) | Standard Part D | Plan's copay; counts toward TrOOP; Extra Help applies if eligible |
| Ozempic, Mounjaro, or Rybelsus for type 2 diabetes | Standard Part D | Plan's copay; counts toward TrOOP; Extra Help applies if eligible |
| Foundayo for weight loss | Medicare GLP-1 Bridge | $50 flat copay |
| Compounded semaglutide or tirzepatide | Neither — not FDA-approved finished products | N/A |
For someone with both obesity and established cardiovascular disease, Wegovy can be prescribed for either indication. The cardiovascular risk reduction route (through Part D) is often the better deal because: (1) the Part D copay can be lower than $50 depending on your plan, (2) whatever you pay counts toward your $2,100 OOP cap, (3) Extra Help applies if you qualify for it, and (4) there’s no 18-month time limit.
See our Does Medicare Cover Wegovy for Weight Loss guide for the deeper Wegovy-vs-Bridge comparison.
Five Real Eligibility Scenarios
BMI 36, prescribed Wegovy injection for weight loss
✅ Likely eligible under Tier 1
BMI ≥ 35 standalone meets the criterion. As long as the plan type is eligible, the prescription is for weight loss specifically, and the prescriber attests to lifestyle modification, this is the cleanest qualifying path. Time to schedule the prior authorization conversation.
Currently BMI 33 after losing weight on Wegovy started in 2024 at BMI 37
✅ Likely eligible under Tier 1
CMS specifically allows this. The BMI criterion is measured at GLP-1 therapy initiation, not at the time of the Bridge prior authorization. Your prescriber will attest that you met BMI ≥ 35 when you started therapy. Bring historical weight records — chart notes, weigh-ins, or labs that show your weight at the time of therapy initiation.
BMI 28 with prior heart attack three years ago, prescribed Zepbound for weight loss
✅ Likely eligible under Tier 3 — but check the formulation
Tier 3 (BMI ≥ 27 + prior MI) is satisfied. Bring cardiology records or hospital discharge summary documenting the heart attack. Critical: make sure the prescription is for Zepbound KwikPen specifically. If your prescriber writes for a vial or single-dose pen, ask them to switch to KwikPen for Bridge coverage.
BMI 31 with controlled hypertension on one medication, prescribed Wegovy for weight loss
❌ Likely NOT eligible under any tier
Tier 2 requires uncontrolled hypertension while on 2 or more antihypertensives. Controlled hypertension on one medication doesn't meet the Tier 2 criterion. BMI 31 is below the Tier 1 threshold of 35. Unless there's another qualifying condition (prediabetes? CKD?), this person doesn't qualify for the Bridge. See 'What if you don't qualify' below.
BMI 34 with established cardiovascular disease, prescribed Wegovy for cardiovascular risk reduction
⚠️ Goes through standard Part D, not the Bridge
Wegovy is FDA-approved for cardiovascular risk reduction in adults with established CV disease and overweight/obesity. CMS specifically prohibits using the Bridge when the indication is Part D-coverable. Your plan's formulary, prior authorization, or exception process determines actual access and cost. The pathway is Part D, not the Bridge — and for this patient, Part D may be the better deal anyway since the copay counts toward their OOP cap.
Bridge Program Timeline (Updated April 21, 2026)
| Date | Event | What to do now |
|---|---|---|
| Dec 23, 2025 | CMS announces the Bridge and BALANCE Model | — |
| Mar 3, 2026 | CMS releases detailed Bridge FAQ | Read the eligibility tiers above |
| Mar 9, 2026 | CMS updates FAQ to clarify pharmacy reimbursement | — |
| Mar 16, 2026 | CMS publishes pharmacy payer sheet | Pharmacies prepare claims systems |
| Apr 6, 2026 | CMS adds Foundayo; limits Zepbound to KwikPen only | Check your prescription formulation |
| Apr 21, 2026 | CMS extends Bridge through December 31, 2027 | Plan for the longer 18-month window |
| Spring 2026 (TBD) | CMS expected to release detailed PA submission workflow | Schedule a May/June provider visit |
| July 1, 2026 ★ | Bridge launches — first PAs can be processed | Be ready with documentation in hand |
| Oct 15 – Dec 7, 2026 | Medicare Open Enrollment for 2027 plan year | Verify your plan type for 2027 |
| Dec 31, 2027 ★ | Bridge program ends | Have a 2028 backup plan in place |
| 2028 and beyond | Coverage continuation depends on future CMS action | Watch for CMS announcements |
What happens after December 31, 2027?
Honest answer: nobody knows yet. Possibilities include another Bridge extension, a revised BALANCE Model with different participation rules, a return to no Medicare weight-loss GLP-1 coverage, or new legislation. Treat the Bridge as 18 months of guaranteed access and make a backup plan for 2028. See our CMS BALANCE Model GLP-1 Explained guide for the latest on what’s expected for Medicaid coverage.
What If You Don’t Qualify for the Bridge?
Fallback comparison for Medicare beneficiaries
| Fallback route | Medicare-compatible? | FDA-approved drug? | Best fit |
|---|---|---|---|
| Standard Part D for non-weight-loss indication | ✓ Yes — through Part D plan | ✓ Yes (Wegovy, Zepbound, Ozempic, etc.) | First check for any Medicare beneficiary with co-existing T2D, CVD, or OSA |
| Ro Body cash-pay program | ! Cash-pay only — Ro cannot coordinate Medicare coverage | ✓ Yes (Foundayo, Zepbound) | Medicare beneficiary willing to self-pay for clinical oversight + FDA-approved meds |
| TrumpRx | ✕ No — explicit government-insurance exclusion | ✓ Yes — but only for cash-paying non-Medicare patients | Non-government-insured cash-pay readers only |
| Compounded GLP-1 telehealth | ! Cash-pay only — not part of the Bridge | ✕ No — not FDA-approved finished products | Adults who have discussed risks with their prescriber and made a deliberate choice |
Option 1 — Check whether standard Part D already covers your GLP-1
If you have type 2 diabetes, established cardiovascular disease, or moderate-to-severe obstructive sleep apnea with obesity, check whether your Part D plan covers the relevant GLP-1 for that indication. Call the number on the back of your Part D card and ask:
- Type 2 diabetes → Ozempic, Mounjaro, or Rybelsus are commonly on Part D formularies
- Established CV disease + overweight/obesity → Wegovy may be covered for cardiovascular risk reduction
- Moderate-to-severe OSA + obesity → Zepbound may be covered for OSA
“Does my plan cover [drug name] for [indication]? What’s the prior authorization or exception process?”
Option 2 — FDA-approved cash-pay through Ro
If standard Part D doesn’t apply and the Bridge doesn’t either, Ro is a comprehensive cash-pay path for FDA-approved branded GLP-1 medication. Their Body program pairs you with a licensed physician and provides ongoing clinical support including dose management.
Ro Body (cash-pay path) — Pairs you with a licensed physician for clinical oversight and access to FDA-approved Foundayo and Zepbound. Ro cannot coordinate Medicare medication coverage, but is a legitimate self-pay option while you wait for the Bridge to launch or if the Bridge doesn’t apply.
Ro Body: $39 for the first month, then as low as $74/month with annual plan (or $149/month). Medication billed separately. This is a cash-pay path, not a Medicare Bridge application path.
Check eligibility and pricing on Ro →Disclosure: The RX Index may earn a commission. Ro is a cash-pay path and is not a Medicare GLP-1 Bridge application path.
A note on compounded GLP-1s for Medicare beneficiaries
Compounded GLP-1 products are not FDA-approved finished drugs. The FDA does not review them for safety, effectiveness, or quality before they’re marketed. Compounded products are not part of the Medicare GLP-1 Bridge and should not be presented as a Bridge substitute.
For Medicare-aged beneficiaries — often on multiple medications, with potential drug interactions and condition-specific risks — this is a conversation to have deliberately with your prescriber, not a default fallback. If you decide to explore that path after talking with your prescriber, see our compounded GLP-1 vs. name brand guide.
Coverage Eligibility vs. Medical Eligibility
Coverage eligibility
What this whole page is about — does CMS allow the program to pay for your medication? That’s the BMI tiers, the plan types, the prescription indication, the documentation. Both have to be yes before you fill a prescription.
Medical eligibility
A separate question your prescriber answers — is this medication safe and appropriate for you, given your specific health history, drug interactions, contraindications, and the FDA labeling? That’s a clinical decision, not a coverage one. We’re not a medical practice and don’t make clinical recommendations.
What We Actually Verified
We’re a research and editorial site, not a primary medical authority. Here’s exactly what we verified, against which sources, and when.
| What we verified | Source | Last verified |
|---|---|---|
| Bridge program dates (July 1, 2026 – Dec 31, 2027) | CMS Medicare GLP-1 Bridge page | Apr 25, 2026 |
| April 21, 2026 extension; BALANCE non-launch in Medicare for 2027 | CMS Bridge page; CMS BALANCE Model page | Apr 25, 2026 |
| April 6, 2026 drug list update (Foundayo added; Zepbound KwikPen only) | CMS Medicare GLP-1 Bridge page | Apr 25, 2026 |
| Three eligibility tiers and AND/OR logic | CMS Medicare GLP-1 Bridge FAQ | Apr 25, 2026 |
| Eligible and ineligible Part D plan types | CMS Medicare GLP-1 Bridge FAQ | Apr 25, 2026 |
| Covered medications and excluded Zepbound formulations | CMS Bridge FAQ; CMS-published NDC list | Apr 25, 2026 |
| $50 copay does not count toward Part D deductible or OOP cap | CMS Bridge FAQ; KFF analysis | Apr 25, 2026 |
| Low-Income Subsidy / Extra Help does not apply | CMS Bridge FAQ; KFF analysis | Apr 25, 2026 |
| Coupons and discount programs cannot be applied | CMS Bridge FAQ | Apr 25, 2026 |
| Humana as central processor; BIN 028918 / PCN MEDDGLP1BR | CMS Bridge FAQ; CMS payer sheet (Mar 16, 2026) | Apr 25, 2026 |
| Net manufacturer price of $245/monthly supply | CMS Bridge FAQ; KFF analysis | Apr 25, 2026 |
| Ro Body pricing and Medicare-coordination limitation | Ro.co weight loss insurance page | Apr 25, 2026 |
| TrumpRx government-insurance exclusion | TrumpRx Wegovy product terms | Apr 25, 2026 |
Primary sources: CMS Medicare GLP-1 Bridge page · CMS BALANCE Model page · CMS pharmacy payer sheet · KFF analysis
Update cadence: Monthly until July 2026 launch, then quarterly. Immediate update triggers: any CMS guidance release, FDA approval affecting the drug list, BALANCE Model status changes, or material provider pricing changes.
Correction policy: If you spot something wrong, visit therxindex.com/corrections — every correction is logged with its date.
Frequently Asked Questions
Who qualifies for the Medicare GLP-1 Bridge program?
What BMI do I need for the Medicare GLP-1 Bridge?
Does Medicare Advantage qualify for the GLP-1 Bridge?
Does prediabetes alone qualify me for the Medicare GLP-1 Bridge?
When does the Medicare GLP-1 Bridge start and end?
Does the Medicare GLP-1 Bridge cover Ozempic or Mounjaro?
Does the Bridge cover Zepbound vials?
Does Wegovy oral tablet count for Bridge coverage?
Does Foundayo qualify for the Bridge?
Do I have to switch Medicare plans to use the Bridge?
Does the $50 copay count toward my Part D out-of-pocket cap?
What if I'm on Extra Help (LIS) — do I still pay $50?
Can I use a manufacturer coupon with the Bridge?
Where does my doctor send the prior authorization?
Can my doctor apply if they aren't enrolled in Medicare?
What if my BMI is lower now because I already lost weight?
Is the Medicare GLP-1 Bridge available in my state?
Can dual-eligible (Medicare + Medicaid) beneficiaries use the Bridge?
What if I currently take Wegovy for cardiovascular risk reduction through Part D?
Is the Bridge the same as the BALANCE Model?
Can I use TrumpRx if I'm on Medicare?
Still Not Sure Which GLP-1 Program Is Right for You?
The Medicare GLP-1 Bridge is meaningful. It’s also narrower than most headlines made it sound. Whether you qualify for the Bridge, need to use standard Part D for a covered indication, or need a cash-pay alternative — the right program depends on your BMI, your conditions, your plan type, your medications, and your timeline.
Six questions. We’ll match you with the coverage pathway that fits your exact situation. Clear next step in under a minute.
Related guides
- Does Medicare Cover Zepbound? Complete Coverage Guide
- Does Medicare Cover Wegovy for Weight Loss? What Changed in 2026
- CMS BALANCE Model GLP-1 Explained — and Why It’s Not Launching in 2027
- GLP-1 FDA Approvals Timeline: Every Drug & Date (2005–2026)
- Best Telehealth for GLP-1 in 2026: 9 Providers Compared
Disclaimer: This guide is for informational purposes only and does not constitute medical, legal, or insurance advice. Eligibility is ultimately determined by your prescriber and CMS’s central processor. Always consult your healthcare provider and your Medicare Part D plan before making coverage decisions. The RX Index may receive compensation from providers mentioned on this page; this does not influence our coverage. Last updated: · Verified against CMS.gov: · Next scheduled review: Monthly until July 2026 launch, then quarterly.